Stocks · News reference
Filed: 2026-08-03 AccNo: 0001493152-26-035743 Size: 335 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-18 AccNo: 0001493152-26-039023 Size: 201 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgarCocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from
Read original at benzingaLongtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP)
Read original at benzinga